Long-acting injectable noninferior to oral HIV therapy in adherence trial
A phase 3b randomized trial in Kenya, South Africa, and Uganda compared injectable cabotegravir plus rilpivirine every 8 weeks with daily oral dolutegravir-based therapy in virally suppressed HIV patients with suboptimal adherence. At 48 weeks, 91.0% of the long-acting group versus 89.2% of the oral group had viral load below 50 copies per milliliter, meeting the noninferiority criterion, though confirmed virologic failure occurred in 5 participants on long-acting therapy versus none on oral therapy.